Merck
Article
Merck is a recurring organization in the Astral Codex Ten archive, appearing 3 times across 3 issues between November 23, 2021 and December 22, 2021. The archive places it in contexts such as “Pfizer/Merck will have thrown everything at this problem alongside the clinical trials”; “Pfizer/Merck will have thrown everything at this problem”; “communications about Merck’s drug molnupiravir”. It most often appears alongside FDA, fluvoxamine, budesonide.
Metadata
- Category: Organizations
- Mention count: 3
- Issue count: 3
- First seen: November 23, 2021
- Last seen: December 22, 2021
Appears In
- Highlights From The Comments On The FDA And Paxlovid
- The FDA Has Punted Decisions About Luvox Prescription To The Deepest Recesses Of The Human Soul
- Addendum To Luvox Post
Related Pages
-
- FDA (3 shared issues)
-
- fluvoxamine (3 shared issues)
-
- budesonide (2 shared issues)
-
- Johns Hopkins (2 shared issues)
-
- Luvox (2 shared issues)
-
- molnupiravir (2 shared issues)
-
- Paxlovid (2 shared issues)
-
- Scott (2 shared issues)
-
- Vox (2 shared issues)
-
- Andrew (1 shared issues)
-
- aspirin (1 shared issues)
-
- Astralcodexten Com (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
Pfizer/Merck will have thrown everything at this problem alongside the clinical trials, as they can afford to do this, so their regulatory submissions will be pretty good. However they still might have to store the new batches for a few months to demonstrate that they have a comparable shelf-life to the old batches, and FDA might wait to see this data etc.
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”